tiprankstipranks
Advertisement
Advertisement
Enanta Advances RSV Antiviral Zelicapavir to Registrational Trial
PremiumCompany AnnouncementsEnanta Advances RSV Antiviral Zelicapavir to Registrational Trial
2M ago
Enanta to advance zelicapavir into registrational Phase 2b/3 clinical trial
Premium
The Fly
Enanta to advance zelicapavir into registrational Phase 2b/3 clinical trial
2M ago
Enanta reports Q2 EPS (45), consensus (49c)
Premium
The Fly
Enanta reports Q2 EPS (45), consensus (49c)
3M ago
Enanta’s New RSV Trial in Infants: What Investors Should Watch in ENTA
PremiumCompany AnnouncementsEnanta’s New RSV Trial in Infants: What Investors Should Watch in ENTA
5M ago
Enanta Shareholders Approve Board Elections and Equity Plan
Premium
Company Announcements
Enanta Shareholders Approve Board Elections and Equity Plan
5M ago
Enanta Pharmaceuticals: RSV Monoclonal Headwinds Turn Tailwind for Zelicapavir Treatment Opportunity
Premium
Ratings
Enanta Pharmaceuticals: RSV Monoclonal Headwinds Turn Tailwind for Zelicapavir Treatment Opportunity
6M ago
Enanta Pharmaceuticals Reports Progress in Drug Development
PremiumCompany AnnouncementsEnanta Pharmaceuticals Reports Progress in Drug Development
9M ago
Enanta reports Q4 EPS (87c), consensus ($1.01)
Premium
The Fly
Enanta reports Q4 EPS (87c), consensus ($1.01)
9M ago
Is ENTA a Buy, Before Earnings?
Premium
Pre-Earnings
Is ENTA a Buy, Before Earnings?
9M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100